Adding BCL2 Inhibitor to Standard Chemo Worsens Survival in Aggressive Lymphoma
A randomized phase II trial found that adding venetoclax to dose-adjusted EPOCH-R reduced progression-free survival and overall survival in newly diagnosed double-hit lymphoma patients. The combination caused excess deaths, primarily from hematologic toxicity and infections, leading to early trial closure. Researchers concluded that this combination is not recommended and that the standard regimen alone provides durable remissions in many patients.
The open-label ALLIANCE A051701 trial enrolled 73 patients across 41 U.S. sites, with a median follow-up of nearly 35 months. Most participants (89%) carried concurrent MYC and BCL2 rearrangements, while the remainder had MYC/BCL6 rearrangements alongside BCL2 protein expression. The median age was 65, and the cohort was predominantly male and white.
Prior research had suggested venetoclax might benefit diffuse large B-cell lymphoma when paired with R-CHOP, particularly in cases with BCL2 protein overexpression. However, in this intensive DA-EPOCH-R setting, the added drug sharply increased hematologic toxicity and infections, leading to six treatment-related deaths versus one in the control arm, forcing the trial to stop early.
This negative trial could reshape treatment protocols for the roughly 5% of newly diagnosed diffuse large B-cell lymphoma patients with double-hit genetics. Clinicians may now avoid adding venetoclax to intensive regimens, potentially sparing patients from severe toxicity and early death. The findings also underscore the need for safer, targeted alternatives, as standard DA-EPOCH-R alone still leaves a substantial survival gap. Patients and oncologists may view these results as a cautionary benchmark for future combination studies.